Navigation Links
IRIDEX Announces Fourth Quarter and Full Year 2007 Conference Call and Release Date
Date:3/28/2008

MOUNTAIN VIEW, Calif., March 28 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its fourth quarter and full year 2007 financial results after the market closes on Thursday, April 10, 2008. In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, April 10, 2008 to discuss the results of the quarter and other business developments.

Interested parties may access the live conference call via telephone by dialing (800) 240-7305 (US) or (303) 262-2130 (International), or by visiting the Company's website at http://www.iridex.com. A telephone replay will be available beginning on Thursday, April 10, 2008 through Thursday, April 17, 2008 by dialing (800) 405-2236 (US) or (303) 590-3000 (International) and entering Passcode 11111765#.

About IRIDEX

IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, disposable laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at http://www.iridex.com.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. IRIDEX Reports Third Quarter Financial Results
2. IRIDEX Announces Third Quarter 2007 Conference Call and Release Date
3. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
4. James B. Hawkins Appointed to IRIDEX Board of Directors
5. IRIDEX Appoints Burr, Pilger & Mayer New Independent Auditor
6. William Moore Appointed to IRIDEX Board of Directors
7. IRIDEX Announces Closing of $5.0 Million Private Placement
8. China Yingxia International Announces Soybean Milk Production Lines Acquisition
9. Barr Announces Reorganization of Senior Management, Business Functions
10. U.S.News & World Report Announces the 2009 Publication of Americas Best Graduate Schools
11. CVCTA Education Announces New LOW DOSE Initiative for CT Angiograms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)... Output of New Molecular Entities Drops to Histori... Competition from Generics Companies, LONDON, Jul...omson,Reuters today announced the availability of ...eutical R&D Factbook, an indispensable reference,a...harmaceutical R&D,corporate finance, business str...
(Date:7/23/2008)... WINSTON-SALEM, N.C. A study out of Wake Forest ...rgency room doctors are correctly identifying pati...ratory tests haven,t yet confirmed it. , The stu...nalyzed patients with heart attack symptoms who we...t participating U.S. centers. , The findings we...
(Date:7/23/2008)... NASDAQ: CRME, TSX: COM, VANCOUVER, July 23 /...DAQ: CRME/TSX: COM) today announced that it has en...nts, LLC, an investment fund managed by,CR Intrins...Advisors, LLC,to purchase Series A convertible pre... Proceeds of the financing will be used for genera...
(Date:7/23/2008)... HOUSTON, July 23 /PRNewswire-FirstCall/ -- The... property and casualty company, today announced it...urricane Dolly, which is,sweeping through southern...-bin/prnh/20051031/NEM023LOGO ), "We are deeply ...y,s,path," said Robin A. Nicks, president of The H...
Breaking Medicine News(10 mins):Health News:Thomson Reuters Publishes CMR International's 2008 Pharmaceutical R&D Factbook, Now Available for the First Time Online 2Health News:Study shows emergency physicians have good first instincts in diagnosing heart attacks 2Health News:Cardiome Announces Preferred Share Financing 2Health News:Cardiome Announces Preferred Share Financing 3Health News:The Hanover Ready to Serve Policyholders Impacted by Hurricane Dolly 2
...d at gauging adolescent health, has said that thos...riage, show a propensity to cover //the truth abou...so rigid about maintaining their virginity. The s...l encounters among students between seventh to twe...
...r Dr Kebede Worku has said that there has been a s...in the country. The prevalence rate is 5 percent//...due to their low socio-economic status in Ethiopia... he said. 'The national surveillance report estima...
...below 65 years, a government job in Assam is assur...t the appointment letter on the spot//. But there ... rural areas. 'Anybody with a medical degree can ...ew on Wednesday and Thursday and get a job. We hav...
... in the June issue of the journal Obstetrics & Gyn...at engaging in sexual intercourse during the final...very//. The study conducted by the Ohio state Uni... belief and states that just the opposite was true...
Other Medicine News:Health News:Assam Recruits Doctors to Serve in Rural Areas 2Health News:A New Study Discredits The Myth Of Sexual Intercourse Late In Pregnancy Speeds Labour & Delivery 2
(Date:7/22/2008)...nt Plan Completed Successfully, DUBLIN, Ireland, ...on,plc (NASDAQ: AMRN ) today announced that the C...d and Drug Administration (FDA) to discuss the,Com...f,hypertriglyceridemia. Following these discussion...1 in hypertriglyceridemia., Dr. Declan Doogan, He...
(Date:7/22/2008)...2 /- Hyperion,Therapeutics, Inc. toda...nt,in its Phase 1/2 clinical trial to evaluate the...ts of HPN-100 (formally called GT4P) versus,BUPHEN...a cycle disorders,(UCD). The company plans to anno...s year., (Logo: http://www.newscom.com/cgi-bin/p...
(Date:7/22/2008)...etic Risk Based on Clinical Data, Preventive Me...s, WALTHAM, Mass., July 22 /PRNewswire-FirstCall/...y announced the launch of an enhanced test report,...eart Health Genetic Test.,The test is currently ma...h,Genetic Test by Quixtar/Amway. The new report wi...
(Date:7/21/2008)... SEAS (Simvastatin and Ezetimibe in,Aortic Stenosi...,cholesterol lowering with the combination of simv...in patients with aortic stenosis., Aortic stenosi...alve in,the heart) is a relatively common disease ...treated, it can progress to death from heart failu...
Breaking Medicine Technology:Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 2Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 3Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study 4Popular Florida Restaurant Leads Hospitality Industry by Converting to Pasteurized Shell Eggs Usage 11283 1Popular Florida Restaurant Leads Hospitality Industry by Converting to Pasteurized Shell Eggs Usage 11283 2EBRI Policy Forum 3A Large Employers Continue to Offer Health Benefits 11281 1EBRI Policy Forum 3A Large Employers Continue to Offer Health Benefits 11281 2Elderly more likely to deny smoking when asked says Case Western Reserve University researcher 11277 1Elderly more likely to deny smoking when asked says Case Western Reserve University researcher 11277 2Shengtai Pharmaceutical Inc to Present at Roth Conference 11273 1Shengtai Pharmaceutical Inc to Present at Roth Conference 11273 2Shengtai Pharmaceutical Inc to Present at Roth Conference 11273 3
...ILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007,...y announced,preliminary results from two open-labe... the potential use of Xcytrin(R),(motexafin gadoli...ate, in combination with Alimta(R) (pemetrexed) an... second-line treatment,for patients with non-small...
...S, the Netherlands, June 27, 2007-Organon, the hum...ed today that two,out of three Phase III clinical ...w long-acting fertility hormone, have reached,thei...s a new recombinant fertility hormone. It is,the f...follicular,stimulant or SFS) of which, due to its ...
Other Medicine Technology:Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 2Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target 3
Electrical I/A unit for planned ECCE with peristaltic pump with linear aspiration (foot control). Independent irrigation, suction, reflux possible with multi-function footswitch that allows the surge
Globe Fixation Ring
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass.
Medicine Products: